Lunch Symposium: Immuno-Oncology for GI Cancers: A Clinical Perspective on Current and Future Practice Supported by Bristol Myers Squibb
11:15 – 12:45 CEST
Lunch Symposium: Modern Management of Cholangiocarcinoma: Sharing Evidence, Experience, and Expertise, Organised by PeerVoice, Supported by Taiho Oncology and Servier
11:15 – 12:45 CEST
Lunch Symposium: Novel Approaches for GI Cancers: Targeted Therapy for KRAS Mutations Supported by Mirati Therapeutics, Inc.
O-1: Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients metastatic pancreatic ductal adenocarcinoma: sensitivity analysis of survival from the NAPOLI 3 trial
Locally Advanced Bile Duct Cancer: Criteria and Approaches in Borderline Resectable Disease
Speaker: Thomas Gruenberger, MD – Clinic Favoriten, Dept Surgery, HPB Center, health network Vienna
Sigmund Freud Private University Vienna
17:55 – 18:05 CEST
O-2: Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)
SO-1: A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH1 and IDH2, as monotherapy and in combination with cisplatin and gemcitabine in advanced IDH-mutant cholangiocarcinoma
SO-2: Quantitative Risk-benefit Assessment of Ivosidenib Compared to Placebo in Patients with IDH1-mutated Intrahepatic Cholangiocarcinoma: Phase 3 ClarIDHy trial
SO-5: Futibatinib in patients with FGFR2-rearranged intrahepatic cholangiocarcinoma: Responder analyses of efficacy and safety from the phase 2 FOENIX-CCA2 study
LBA-1: The Phase III study: Targeted Intra-Arterial Gemcitabine vs. Continuation of IV Gemcitabine plus Nab-Paclitaxel following Induction with Sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer (TIGeR-PaC)
SO-6: Changes in the Course of Advanced Pancreatic Cancer Treatment With Systemic Chemotherapy: A Pooled Analyses of Five Clinical Trials From Two Decades of Clinical Research Within the German AIO Study-Group
SO-7: First-line liposomal irinotecan (nal-IRI), oxaliplatin and S-1 (NASOX) in unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC): A phase I/II study
Chair: Anna D. Wagner, MD – Lausanne University Hospital, University of Lausanne
08:00 – 08:10 CEST
O-3: Additional data from the KEYNOTE-859 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer
Abstract Presenter: Lucjan Wyrwicz, MD PhD – Maria Sklodowska-Curie National Cancer Research Institute
08:10 – 08:20 CEST
O-4: GEMSTONE-304: a phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)
SO-10: Phase 2 study of futibatinib in patients with specific FGFR aberrations: Activity in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplification
O-5: Integrating trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2+ gastric cancer (GC) - subgroup analyses of EORTC 1203 “INNOVATION”, a collaboration with KCSG and DUCG
Abstract Presenter: Anna D. Wagner, MD – Lausanne University Hospital, University of Lausanne
08:48 – 08:56 CEST
SO-9: The relationship between primary tumour infiltrating immune cells and immune activation status of tumour draining lymph nodes in oesophageal cancer patients – results from the UK MRC OE02 trial
SO-11: Bemarituzumab for treatment of previously untreated advanced and/or metastatic gastric and gastroesophageal cancer (GC): Final analysis of a randomized phase 2 trial (FIGHT)
SO-12: CLDN18.2 expression in resectable gastroesophageal cancers: associated clinical and molecular signatures and impact of neoadjuvant chemotherapy on intratumor heterogeneity
O-6: EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients (pts) with resected gastroesophageal adenocarcinoma (GEA) following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—An open-label randomized controlled phase II study
O-7: Adjuvant nivolumab vs placebo in resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: First report of comprehensive biomarker analyses from CheckMate 577
SO-14: Randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): RATIONALE-301 age ≥65 years subgroup
SO-16: Proton beam radiotherapy as a valid curative local alternative modality in newly diagnosed hepatocellular carcinoma: comparative study with radiofrequency ablation
SO-17: A new risk classification integrating ctDNA, CEA and pTN stage for DFS prognosis and predictive value for treatment duration in stage III colon cancer
SO-18: ctDNA-guided adjuvant treatment after radical intent treatment of metastatic spread from colorectal cancer is feasible – results from the preplanned interim analysis of the OPTIMISE Study
Precision Medicine Development in Gastrointestinal Oncology: Evidence-Based Guidelines Using Liquid Biopsies in Treatment, Decision Making, Optimizing Management, and Sequencing
Lunch Symposium: In the Medical Spotlight: Antibody-Drug Conjugates in Advanced HER2-Positive Gastric/ Gastroesophageal Junction Cancer Supported by Daiichi Sankyo
13:30 – 15:00 CEST
Lunch Symposium: New Hope for Metastatic Pancreatic Cancer Patients Supported by Servier International Medical Affairs
13:30 – 15:00 CEST
Lunch Symposium: Putting the Pieces Together to Optimise the Management of BRAF V600E-mutant mCRC Supported by Pierre Fabre
13:30 – 15:00 CEST
Lunch Symposium: Value of Disease Stabilization Across GI Tumors Supported by Bayer
15:15 – 16:40 CEST
Session XVII: Adjuvant and Neoadjuvant Treatment of Colon Cancer
Chair: John L. Marshall, MD – Lombardi Comprehensive Cancer Center, Georgetown University
SO-22: Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: a translational analysis of the AtezoTRIBE study
LBA-4: Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)
O-9: Health‑related quality of life associated with trifluridine/tipiracil in combination with bevacizumab in refractory metastatic colorectal cancer: An analysis of the phase 3 SUNLIGHT trial
Abstract Presenter: Gerald Prager, MD – Medizinische Universität Wien
18:30 – 18:50 CEST
O-10: Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N+C) versus chemo (C)
SO-24: Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: overall survival and subgroup analysis of the randomized phase 2 VELO trial
SO-25: Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment for RAS and BRAF wild-type metastatic colorectal cancer: Updated survival analysis of the DEEPER trial by JACCRO
Abstract Presenter: Yu Sunakawa, MD, PhD – St. Marianna University School of Medicine
08:16 – 08:24 CEST
SO-26: Intermittent or continuous panitumumab plus FOLFIRI for first-line treatment of patients with RAS/BRAF wild-type metastatic colorectal cancer: an update of survival/toxicity and preliminary results of genomic alterations from IMPROVE study
SO-27: Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: results of the phase II AVETRIC trial by GONO
Discussant: Shouki Bazarbashi, MBBS – King Faisal Specialist Hospital and Research Center-Riyadh
08:42 – 08:50 CEST
SO-28: FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable mCRC patients: updated and overall survival results of the phase II randomized AtezoTRIBE study
SO-29: Clinical characteristics, efficacy, and safety in patients receiving second- or third-line encorafenib plus cetuximab (E+C) vs control for metastatic colorectal cancer (mCRC): BEACON CRC post hoc analysis
SO-31: Comprehensive genomic profiling of tumor tissue and plasma circulating tumor DNA in RAS/BRAFV600E wild type metastatic colorectal cancer patients: initial findings from the CAPRI 2-GOIM trial
SO-32: Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAFV600E mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT).
SO-33: The effect of RAS/BRAF mutation status on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer – a post-hoc exploratory analysis of the randomized NORDIC9-study
Abstract Presenter: Gabor Liposits, MD – Department of Clinical Research, University of Southern Denmark
O-12: NCI9673 (Part B): A multi-institutional ETCTN randomized phase II study of nivolumab with or without ipilimumab in refractory, metastatic squamous cell carcinoma of the anal canal
Abstract Presenter: Van Morris, MD – MD Anderson Cancer Center